Use of atypical antipsychotics in the treatment of autistic disorder

Annals of Pharmacotherapy

Volumn 41, Issue 4, 2007, Pages 626-634

  Stachnik, Joan M ^a   Nunn Thompson, Cheryl ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Aripiprazole; Atypical antidepressants; Autism; Olanzapine; Quetiapine; Ziprasidone

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; HALOPERIDOL; LORAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; ZIPRASIDONE;

AGGRESSION; AGITATION; AKATHISIA; AUTISM; BEHAVIOR DISORDER; CHILD; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; HUMAN; HYPERSALIVATION; INCREASED APPETITE; INSOMNIA; MAJOR CLINICAL STUDY; MANIA; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; OPEN STUDY; PAIN; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RETROSPECTIVE STUDY; REVIEW; SCORING SYSTEM; SEDATION; SELF INJECTION; SIDE EFFECT; SLURRED SPEECH; SPEECH DISORDER; SUICIDAL IDEATION; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; TREMOR; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; CHILD BEHAVIOR; CHILD, PRESCHOOL; CLINICAL TRIALS; HUMANS; TREATMENT OUTCOME;

EID: 34247255894     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H527     Document Type: Review

References (50)

1. Volkmar F, Pauls D. Autism. Lancet 2003;362:1133-41.
2. Hollander E, Phillips A, Yeh C. Targeted treatments for symptom domains in child and adolescent autism. Lancet 2003;363:732-4.
3. Package insert. Risperdal (risperidone). Titusville, NJ: Janssen LP, October 2006.
4. Chavez B, Chavez-Brown M, Rey JA. Role of risperidone in children with autism spectrum disorder. Ann Pharmacother 2006;40:909-16. Epub 7 Mar 2006. DOI 10.1345/aph.1G389
5. Lord C, Cook E, Leventhal B, Amaral D. Autism spectrum disorders. Neuron 2000;28:355-63.
6. Mikhail A, King B. Autism spectrum disorders: update of evaluation and treatment. Curr Psych Reports 2001;3:361-5.
7. King BH, Bostic JQ. An update on pharmacologic treatments for autism spectrum disorders. Child Adolesc Psychiatr Clin North Am 2006;15: 161-75.
8. National Institute of Child Health and Human Development, National Institutes of Health. Autism questions and answers for health care professionals. June 2001. www.nichd.nih.gov/publications/pubs_details.cfm? from=autism&pubs_id=212 (accessed 2006 Sept 8).
9. Chakrabarti S, Fombonne E. Pervasive developmental disorders in preschool children: confirmation of high prevalence. Am J Psychiatry 2005;162:1133-41.
10. Volkmar F, Lord C, Bailey A, Schultz R, Klin A. Autism and pervasive developmental disorders. J Child Psych Psychiatry 2004;45:135-70.
11. Tidmarsh L, Volkmar F. Diagnosis and epidemiology of autism spectrum disorders. Can J Psychiatry 2003;48:517-25.
12. Fombonne E. Epidemiological surveys of autism and other pervasive developmental disorders: an update. J Autism Dev Disord 2003;33:365-82.
13. Newschaffer C, Falb M, Gurney J. National autism prevalence trends from United States special education data. Pediatrics 2005;115:e277-82.
14. Goldson E. Autism spectrum disorders: an overview. Adv Pediatr 2004; 51:63-109.
15. Buitelaar J, Willemsen-Swinkels S. Autism. Current theories regarding its pathogenesis and implications for rational pharmacotherapy. Paediatr Drugs 2000;2:67-81.
16. Fombonne E, Zakarian R, Bennett A, Meng L, McLean-Heywood D. Pervasive developmental disorders in Montreal, Quebec, Canada: prevalence and links with immunizations. Pediatrics 2006;18:e139-50.
17. Parker SK, Schwartz B, Todd J, Pickering LK. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics 2004;114:793-804.
18. Committee on Children with Disabilities. American Academy of Pediatrics: technical report: the pediatrician's role in the diagnosis and management of autistic spectrum disorder in children. Pediatrics 2001;107:E85. http://pediatrics.aappublications.org/cgi/reprint/107/5/e85 (accessed 2006 Sept 8).
19. Moore ML, Eichner SF, Jones JR. Treating functional impairments of autism with selective serotonin-reuptake inhibitors. Ann Pharmacother 2004;38:1515-9. Epub 3 Aug 2004. DOI 10.1345/aph.1D543
20. Palermo M, Curatolo P. Pharmacologic treatment of autism. J Child Neurol 2004;19:155-64.
21. Aman M, Lam K, Van Bourgondien M. Medication patterns in patients with autism: temporal, regional, and demographic influences. J Child Adolesc Psychopharmacol 2005;15:116-26.
22. Masi G. Pharmacotherapy of pervasive developmental disorders in children and adolescents. CNS Drugs 2004;18:1031-52.
23. Horrigan J, Barnhill L, Courvoisie H. Olanzapine in PDD. J Am Acad Child Adolesc Psychiatry 1997;36:1166-7.
24. Malek-Ahmadi P, Simonds J. Olanzapine for autistic disorder with hyperactivity (letter). J Am Acad Child Adolesc Psychiatry 1998;37:902.
25. Stavrakaki C, Antochi R, Emery P. Olanzapine in the treatment of pervasive developmental disorders: a case series analysis. J Psychiatry Neurosci 2004;29:57-60.
26. Demb H, Roychoudhury K. Comments on "Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study" (letter). J Clin Psychopharmacol 2000; 20:580-1.
27. Potenza M, Holmes J, Kanes S, McDougle C. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 1999;19:37-44.
28. Malone R, Cater J, Sheikh R, Choudhury M, Delaney M. Olanzapine versus Haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 2001;40:887-94.
29. Kemner C, Willemsen-Swinkels S, DeJonge M, Tuynman-Qua H, Van Engeland H. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 2002;22:455-60.
30. Hollander E, Wasserman S, Swanson M, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 2006;16:541-8.
31. Stigler K, Posey D, McDougle C. Aripiprazole for maladaptive behavior in pervasive developmental disorders. J Child Adolesc Psychopharmacol 2004;14:455-63.
32. Shastri M, Alla L, Sabaratnam M. Aripiprazole use in individuals with intellectual disability and psychotic or behavioral disorders: a case series. J Psychopharmacol 2006;20:863-7.
33. Goforth H, Rao M. Improvement in behaviour and attention in an autistic patient treated with ziprasidone. Aust N Z J Psychiatry 2003;37:775-6.
34. McDougle C, Kem D, Posey D. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 2002;41:921-7.
35. Cohen SA, Fitzgerald BJ, Khan SR, Khan A. The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. J Clin Psychiatry 2004;65:110-3.
36. Hardan A, Jou R, Handen B. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disorder 2005;35:387-91.
37. Corson A, Barkenbus J, Posey D, Stigler K, McDougle C. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 2004;65:1531-6.
38. Martin A, Koenig K, Scahill L, Bregman J. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 1999;9:99-107.
39. Findling R, McNamara N, Gracious B, et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 2004;14:287-94.
40. London J. Mania associated with olanzapine. J Am Acad Child Adolesc Psychiatry 1998;37:135-6.
41. Correli C, Penzner J, Parikh U, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin North Am 2006;15:177-206.
42. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol 2004;14:372-94.
43. Scahill L, Lord C. Subject selection and characterization in clinical trials in children with autism. CNS Spect 2004;9:22-32.
44. Aman MG, Novotny S, Samango-Sprouse C, et al. Outcome measures for clinical drug trials in autism. CNS Spect 2004;9:36-47.
45. Williams SK, Scahill L, Vitiello B, et al. Risperidone and adaptive behavior in children with autism. J Am Acad Child Adolesc Psychiatry 2006;45;431-9.
46. Scahill L, McDougle CJ, Williams S, et al. Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 2006;45;1114-23.
47. Hollander E, Phillips A, King B, et al. Impact of recent findings on study design of future autism clinical trials. CNS Spect 2004;9:49-56.
48. Arnold L, Vitiello B, McDougle C, et al. Parent-defined target symptoms respond to risperidone in RUPP autism study: customer approach to clinical trials. J Am Acad Child Adolesc Psychiatry 2003;42;1443-50.
49. McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347:314-21.
50. Hollway J, Koenig K, McGough J, Ritz L, Vitiello B. Risperidone for the core symptom domains of autism: results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. Am J Psychiatry 2006;162:1142-8.